Avert-IT

Intensive Care patients can experience Adverse Events associated with sudden episodes of low blood pressure. These Adverse Events may impact all of the main organs resulting in longer lengths of stay, increased care costs and reducing quality of outcomes. Existing technologies enable to clinicians to know when these events have occurred and treat the effects.

Medical techniques for avoiding Adverse Events currently exist, but clinicians don#t have a reliable way to predict the occurrence, so there is no opportunity for intervention.

Research indicates average lengths of stay can be reduced by up to 30%, and outcomes improved for a similar proportion of patients, if these Adverse Events can be avoided through prediction and intervention. Potential savings across the EU exceed 5 billion euros, annually.

A model for predicting Adverse Events offers potential for improving outcomes across a wide range of conditions and or illnesses.

The main objectives of the project are:

  • Understanding the association between multiple patient parameters and arterial hypotension (sudden drop in blood pressure)
  • Development of a software application to predict the occurrence of arterial hypotension based on recognition of the associations described above
  • Validation of the solution in clinical trials
  • Exploitation model for the commercialisation of the software in product/service sales across international markets

For further information, please visit:
http://avertit.wordpress.com (Avert-IT Project Blog)

Project co-ordinator:
Pera Innovation Ltd.

Partners:

  • C3 Amulet Ltd
  • Uppsala Universitet
  • Universitätsklinikum Heidelberg
  • Azienda Ospedaleria San Gerardo Di Monza
  • Kauno Technologijos Universitetas
  • The University Of Glasgow
  • Greater Glasgow Health Board
  • Hospital Universitari Vall d'Hebron
  • Philips Medizin Systeme Böblingen Gmbh.

Timetable: from 01/2008 € to 12/2010

Total cost: € 2.286.138

EC funding: € 1.780.000

Programme Acronym: FP7-ICT

Subprogramme Area: Advanced ICT for risk assessment and patient safety

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

Bayer Acquires Blackford Analysis Ltd. B…

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...

Veradigm Announces Strategic Investment …

Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million...